Food and Staples Retailing Drug Retail

More

  • Ali Health, an affiliate of e-commerce giant Alibaba Group Holding Ltd, said late on Sunday the move may severely impact its business, although it added it had not received notice from the CFDA over the operation of the platform. Hunan- based pharmacy chain Yontinhe Group said in January it was suing the CFDA over the monitoring system, alleging the arrangement...

  • Ali Health said in a filing on Sunday it had not received notice from the CFDA over the operation of the platform. Hunan- based pharmacy chain Yontinhe Group said last month it was suing the CFDA over the monitoring system, alleging the arrangement gave an unfair advantage to Ali Health, which has its own online drug sales business. Ali Health said it had not...

  • Hunan- based pharmacy chain Yontinhe Group said last month that it was suing the CFDA over the monitoring system, alleging the arrangement gave an unfair advantage to Ali Health, which has its own online drug sales business. Shares in Ali Health, an affiliate of e-commerce giant Alibaba Group Holding, fell sharply in the aftermath of the announcement, fueled by...

  • CVS forecast an adjusted profit of $1.14- $1.17 per share for the first quarter, below the average analyst estimate of $1.18, according to Thomson Reuters I/B/E/S. The net income attributable to the company rose 13.4 percent to $1.50 billion, or $1.34 per share, in the fourth quarter ended Dec. 31, helped by strong demand in its pharmacy business.

  • Feb 9- CVS Health Corp, the No.2 U.S. drugstore chain by store count, reported an 11 percent rise in quarterly net revenue, helped by strong demand in its pharmacy business. The net income attributable to the company rose to $1.50 billion, or $1.34 per share, in the fourth quarter ended Dec. 31 from $1.32 billion, or $1.14 per share, a year earlier. Net revenue rose to $41.15...

  • Ex-drug CEO Shkreli tweets response House committee

    The House Oversight Committee wants Turing Pharmaceuticals founder Martin Shkreli to testify on the issue of raising drug prices, reports CNBC's Eamon Javers.

  • Rocky road for Chimerix

    CNBC's Meg Tirrell reports on the ups and downs for Chimerix's experimental drug brincidofovir.

  • Blackmores opens first Australian retail store

    CEO and MD Christina Holgate tells CNBC why the Supplement brand Blackmores decided to open its first retail store.

  • Martin Shkreli

    Health groups called for Turing Pharmaceuticals to follow through on its promise to lower the price of a recently acquired drug.

  • Martin Shkreli

    CNBC's Meg Tirrell reports a number of health groups have appealed to Turing Pharmaceuticals asking the company to lower its drug price of Daraprim.

  • Cure for blindness?

    Spark Therapeutics is working on an experimental gene therapy for an inherited eye disorder, and it has the potential to be the first gene therapy on the market in the U.S.

  • Spark Therapeutics' eying FDA approval

    Spark Therapeutics' gene therapy for rare, inherited forms of blindness met the goals of a late-stage study.

  • Promising results on arthritis drug

    AbbVie said its experimental drug improved symptoms of rheumatoid arthritis in patients in two mid-stage studies.

  • Biotech CEO speaks out after Turing price hike

    CNBC's Meg Tirrell speaks to Alnylam Pharmaceuticals CEO John Maraganore, about drug pricing in the U.S.

  • Hillary Clinton outlines prescription cost plan

    Democratic presidential candidate Hillary Clinton unveils her plan to lower prescription drug costs.

  • Hillary Clinton: I want to put an end to profiteering

    Democratic presidential candidate Hillary Clinton addresses innovation in the pharmaceutical and biotech industries, and unveils her plan to lower prescription drug costs.

  • Your money or your life?

    Dr. Peter Bach, MD of Memorial Sloan Kettering Cancer Center, weighs in on Turing Pharmaceuticals' decision to increase a single dose of Daraprim from $13.50 to $750.

  • Democratic Presidential candidate Hillary Clinton speaks during a community forum on substance abuse September 17, 2015 in Laconia, New Hampshire.

    CNBC's Meg Tirrell reports on Hillary Clinton's drug plan, one day after she criticized drug price gouging.

  • High costs for drug development

    Hillary Clinton is criticizing drug price gouging. Steve Case, Revolution Chairman and CEO, shares his take.

  • Drug price outrage

    Hillary Clinton is criticizing drug price gouging, after news a drug company hiked the price of one of its drugs by 5,000 percent overnight, with CNBC's Meg Tirrell.